{
    "organizations": [],
    "uuid": "379689f896038ee100e34cb1eec61358e364a1e2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-theratechnologies-announces-fda-ap/brief-theratechnologies-announces-fda-approval-of-trogarzo-injection-idUSASB0C90X",
    "ord_in_thread": 0,
    "title": "BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Theratechnologies Inc:\n* THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZOâ„¢ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T04:18:00.000+02:00",
    "crawled": "2018-03-06T22:44:55.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "theratechnologies",
        "inc",
        "theratechnologies",
        "announces",
        "fda",
        "approval",
        "breakthrough",
        "therapy",
        "injection",
        "first",
        "inhibitor",
        "monoclonal",
        "antibody",
        "multidrug",
        "resistant",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}